Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Brain tissue and pathology

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

It is often associated with recurrent ICH, seizures, and cognitive impairment.It is thought to arise from prior exposure to cadaveric materials, such as lyophilized dural grafts, used in neurosurgical procedures, and shares pathophysiological mechanisms with prion diseases, where Aβ deposition is mediated by the transmission of misfolded proteins (6).Diagnosing iCAA requires a detailed medical history to identify potential exposure to sources of Aβ, with clinical symptoms frequently manifesting decades after the initial surgery, typically with a latency period of 30 to 40 years.A critical analysis of current research reveals that iCAA has shifted from a theoretical concern to a documented reality with significant implications for both patient care and medical ethics.By understanding iCAA's prion-like transmission mechanism and reassessing surgical practices, the medical community can take proactive steps to reduce the incidence of this devastating, but preventable condition.In light of these findings, this opinion paper argues for an increased clinical awareness of iCAA as a potential diagnosis in younger patients presenting with atypical ICH.The emergence of iCAA underscores the unintended long-term effects of neurosurgical practices once thought safe. This demands a paradigm shift in the neurological and neurosurgical approach, where diagnostic workups should include a history of neurosurgical interventions involving cadaveric dural grafts and incorporate advanced imaging and biomarker analysis specific to Aβ accumulation.The iCAA clues include the onset of symptoms earlier in life (<50 years), a history of neurosurgical treatment using cadaveric material, clinical and neuroradiologic features associated with CAA, evidence of Aß brain tissue, as well as the exclusion of CAA genetic causes ( 4). However, early-onset forms, though uncommon, are being increasingly recognized and may result from genetic or iatrogenic causes that warrant specific and focused investigation and management (7). Notably, patients with iCAA are significantly younger than those with sporadic CAA, which is often related to the historical use of lyophilized dural transplants during childhood (8,9). These progressive neurodegenerative disorders result from prions-misfolded proteins that are the smallest infectious agents, even smaller than viruses, and lack nucleic acids (DNA or RNA) in their structure (16). Prions are highly resistant to conventional disinfection methods, posing sign

What this study adds

Evidence grade: Moderate

This opinion paper describes iatrogenic cerebral amyloid angiopathy as a documented condition that may arise from prior exposure to cadaveric materials such as lyophilized dural grafts used in neurosurgery, often appearing 30 to 40 years later. It argues for increased clinical awareness and for reassessing surgical practices to reduce this preventable condition.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Frol, S., & Splavski, B. (2025). To reveal and acknowledge an iatrogenic cerebral amyloid angiopathy: a vascular neurologist and neurosurgeon collaborative perspective. Frontiers in Neurology. https://doi.org/10.3389/fneur.2025.1527417

Vancouver

Frol S, Splavski B. To reveal and acknowledge an iatrogenic cerebral amyloid angiopathy: a vascular neurologist and neurosurgeon collaborative perspective. Frontiers in Neurology. 2025. doi:10.3389/fneur.2025.1527417. PMID: 40584521.

BibTeX

@article{frol2025-40584521,
  author  = {Frol, Senta and Splavski, Bruno},
  title   = {{To reveal and acknowledge an iatrogenic cerebral amyloid angiopathy: a vascular neurologist and neurosurgeon collaborative perspective}},
  journal = {Frontiers in Neurology},
  year    = {2025},
  doi     = {10.3389/fneur.2025.1527417},
  pmid    = {40584521},
  url     = {https://doi.org/10.3389/fneur.2025.1527417}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This opinion paper describes iatrogenic cerebral amyloid angiopathy as a documented condition that may arise from prior exposure to cadaveric materials such as lyophilized dural grafts used in neurosurgery, often appearing 30 to 40 years later. It argues for increased clinical awareness and for reassessing surgical practices to reduce this preventable condition.

Study details

How this study scored 36/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 36 of 100.36 of 100 points earned64 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in Neurology)
Journal's citation record 2 / 4 Frontiers in Neurology: journal h-index 162 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.7 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Bruno Splavski: h-index 17 (OpenAlex, whole career)
Institution's track record 0 / 3 University of Ljubljana: institution h-index 544 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40584521)
Free to read 2 / 2 Free to read
Total 36 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Brain tissue and pathology from nearby years

Also tagged “small”

900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Brain tissue and pathology

See all studies in Brain tissue and pathology →